Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) in previously treated AL amyloidosis
jRCT2071230131Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of etentamig in light-chain amyloidosis (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with dose-limiting toxicities, Percentage of participants who achieve hematologic complete response and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
etentamig
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2071230131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230131.